The United States of America, as Represented by the Secretary, Department of Health and Human Services

Starks Associates Inc.

Spirogen Limited

The United States of America as Represented by the Department of Health

Midwest Research Institute

Children's Hospital Los Angeles

The United States of America as Represented by the Secretary of

B Rao Vishnuvajjala

Kenneth M Snader

Shanker Gupta

Philip Wilson Howard

David Edwin Thurston

Paul S Liu

Barry J Maurer

C Patrick Reynolds

Charles Theodore Kane, Jr

S Esmail Tabibi

Jeffrey G Supko

Luke Y Hsiao

Louis Malspeis

Gregory Turner

Emmanuel I Ezennia

Tsutomu Akama

Stephen John Gregson

Edward A Sausville

Melinda G Hollingshead

Aaron Garzon-Aburbeh

Disclosed are compounds of Formula I wherein X, Y, R-R, T, T, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula I and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula I; a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula I; a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula I; and a method of preparing a compound of Formula I as described herein.

Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto

Disclosed are compounds of Formula (I) wherein X, Y, Ri-R, T, T, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a compound of Formula (I); a method of treating cancer in a mammal, which method comprises administering in an amount effective to treat cancer a compound of Formula (I); a method of treating a viral, parasitic, or bacterial infection of a cell, which method comprises administering in an amount effective to treat a viral, parasitic, or bacterial infection a compound of Formula (I); and a method of preparing a compound of Formula (I) as described herein. 

The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.

Pharmaceutical compositions of safingol and methods of using the same

A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M' are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.

Pyrrolobenzodiazepines

A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR&#xae; EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.

Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same

A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

Geldanamycin derivative and method of treating cancer using same

The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.

Water-insoluble drug delivery system

The invention provides an aminoflavone having formula (I), wherein each of R and R is H, COCH &mdash;R , wherein R is amino alkylamino, dialkylamino, or alkyl- or dialkylaminoalkyl, or an &agr;-amino acid residue, provided that at least one of R or R is other than H, and R is H, branched or straight-chain alkyl, hydroxyalkyl, alkanoyloxyalkyl, alkanoyloxy, alkoxy, or alkoxyalkyl, or pharmaceutically acceptable salts thereof. The present invention also provides a pharmaceutical composition comprising an aminoflavone as described above, and a method of inhibiting the growth of a tumor in a host by administering a tumor growth-inhibiting amount of an aminoflavone compound having the formula as described above.

Aminoflavone compounds, compositions, and methods of use thereof

Provided are brefeldin A derivatives of the formula: ##STR1## wherein one of R.sub.1 and R.sub.2 is H and the other of R.sub.1 and R.sub.2 is a substituent group having 1 to 12 carbon atoms containing a basic nitrogen atom or a quaternary ammonium group, or a salt thereof. These derivatives exhibit good antitumor activity, and are administrable to human patients without the problems associated with brefeldin A.

Brefeldin A derivatives and their utility in the treatment of cancer

Water-soluble derivatives of camptothecin have the formulae: ##STR1## wherein R' is selected from the group consisting of R=CO CH.sub.2 NH.sub.2.HCl

Growing community of inventors

Rockville, MD, United States of America

B Rao Vishnuvajjala